Why the study?
Do prasugrel and ticagrelor reduce ischemic events and mortality compared to clopidogrel in patients with acute coronary syndrome?
Do prasugrel and ticagrelor reduce ischemic events and mortality compared to clopidogrel in patients with acute coronary syndrome?
In acute coronary syndrome, prasugrel and ticagrelor provide superior ischemic protection but higher bleeding risk than clopidogrel, with ticagrelor uniquely showing a mortality benefit.
Supports ticagrelor preference in ACS for mortality benefit despite bleeding; reinforces meta-analytic evidence over clopidogrel.
Prasugrel and ticagrelor reduced ischemic events and increased bleeding in comparison with clopidogrel. A significant mortality reduction was observed with ticagrelor only. There was no efficacy and safety difference between prasugrel and ticagrelor. Registration: URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42019155648.
No takes yet. Share an insight, caveat, or question.
Navarese et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: